Vicept Therapeutics Report issue

For profit Phase 2
Founded: Malvern PA United States (2009)
Status: Acquired by Allergan (2011) → now GlaxoSmithKline (2000)

Organization Overview

First Clinical Trial
2010
NCT01186068
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Vicept Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

oxymetazoline (ocuclear) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rosacea (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1